Brand Intelligence Graphcompany
Company Overview
About Becton Dickinson
Becton, Dickinson and Company (BD) is a Franklin Lakes, New Jersey-based global medical technology company — publicly traded on the New York Stock Exchange (NYSE: BDX) as an S&P 500 Health Care component — manufacturing and selling medical supplies, devices, laboratory equipment, and diagnostic products through approximately 74,000 employees serving healthcare institutions, clinical laboratories, pharmaceutical companies, and life science researchers in over 190 countries. In fiscal year 2025 (ended September 30, 2025), BD reported full-year revenue of $21.8 billion (up 8.2% year-over-year) with Q4 FY2025 revenue of $5.9 billion (+8.3% reported, +3.9% organic growth), and declared a quarterly dividend of $1.05 per share (+1%). Founded in 1897 in New York City by Maxwell Becton and Fairleigh Dickinson Sr. as a thermometer and surgical instrument maker, BD has grown through 125+ years of acquisitions to become a Fortune 500 ($21.8B revenue, #211 on 2024 Fortune 500) global medtech leader. The company operates through three segments: BD Medical (~50% of revenue, IV catheters, syringes, prefillable drug delivery systems, and medication management solutions), BD Life Sciences (flow cytometry, microbiology, molecular diagnostics, and lab automation), and BD Interventional (advanced patient monitoring, interventional cardiology, and peripheral vascular interventions). BD invests $1.2+ billion annually in R&D. In 2024, BD acquired Edwards Lifesciences' critical care monitoring unit for $4.2 billion.
Business Model & Competitive Advantage
BD's hospital medical consumables and diagnostics model addresses the safety, accuracy, and infection control requirements that acute care hospitals embed into procurement decisions: a 500-bed hospital system purchasing IV catheters (BD Nexiva, the #1 global IV catheter brand) selects based on catheter failure rates (dislodgement, infiltration, infection) rather than unit price — because a catheter failure requiring recatheterization costs $150-300 in nursing time and materials while creating an infection risk that drives significantly higher costs. BD's BD Alaris infusion pump system (the most widely deployed smart pump platform in US hospitals) creates high switching costs through clinical workflow integration: hospitals building drug libraries, dose error reduction software, and BCMA barcode scanning workflows on Alaris cannot migrate without revalidating every drug protocol, retraining clinical staff, and rebuilding the pharmacy interface. The 2025 Reverse Morris Trust transaction with Waters Corporation (merging BD's Biosciences and Diagnostic Solutions divisions into a new independent publicly traded company at $17.5 billion) sharpens BD's focus on medical devices and patient monitoring.
Competitive Landscape 2025–2026
In 2025, BD competes in the medical devices, IV delivery, infusion systems, and diagnostics market with Baxter International (NYSE: BAX, IV solutions and infusion pumps, $10.6B revenue), ICU Medical (NASDAQ: ICUI, IV solutions and Plum smart infusion, $2.8B revenue), and Abbott Laboratories (NYSE: ABT, diagnostics and medical devices, $22B revenue) for hospital group purchasing organization contracts, IV catheter and infusion pump platform decisions, and clinical laboratory analyzer placements. The Edwards Lifesciences critical care acquisition ($4.2B, 2024) expands BD's hemodynamic monitoring portfolio with the Swan-Ganz catheter and Acumen IQ pressure-sensing platform — adding ICU-focused clinical decision support to the hospital monitoring portfolio. The BD Medical segment faces ongoing competitive pressure from ICU Medical in smart infusion following Smiths Medical integration. The 2025 strategy focuses on executing the Biosciences/Diagnostics spinoff to Waters, growing the BD Interventional peripheral vascular and urology product lines, and maintaining IV catheter and infusion platform market share.
The Becton Dickinson Story
Founders
Recent Activity
View all →Company Timeline
Major milestones in Becton Dickinson's journey
Leadership Team
Meet the leaders behind Becton Dickinson
Tom Polen
Tom Polen serves as Chairman, Chief Executive Officer, and President of BD. He was named CEO in February 2020 and appointed chairman in April 2021, bringing extensive leadership experience in healthcare and medical technology.
Christopher DelOrefice
Christopher DelOrefice joined BD as Executive Vice President and CFO in September 2021. He earned his BS and MBA from Villanova University and is a certified public accountant. Prior to BD, he spent nearly two decades at Johnson & Johnson, serving as VP of Investor Relations and CFO of both the Consumer and Medical Devices segments for North America.
Mike Garrison
Mike Garrison leads BD's Medical Segment, which represents approximately 50% of total company revenue with products including IV catheters, syringes, and medication management solutions.
Rick Byrd
Rick Byrd oversees BD's Interventional Segment, focusing on advanced patient monitoring, interventional cardiology, and peripheral vascular disease treatments.
Shana Neal
Shana Neal leads BD's human resources strategy, focusing on talent development, diversity and inclusion initiatives, and building a culture that empowers BD's global workforce.
Denise Russell Fleming
Denise Russell Fleming has served as Chief Information Officer and Executive Vice President of Technology and Global Services since 2022, driving BD's digital transformation and technology strategy.
Pamela Spikner
Pamela Spikner has served as Senior Vice President, Chief Accounting Officer, and Controller of BD since January 2025, overseeing accounting operations and financial reporting.
Key Differentiators
Market Leader
Becton Dickinson is recognized as a market leader in the Healthcare Tech sector, demonstrating strong industry presence and customer trust.
Enterprise Scale
With $21.8B in revenue, Becton Dickinson operates at enterprise scale with proven market validation.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Idexx Laboratories
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu
GE HealthCare
GE HealthCare Technologies Inc. is a Chicago, Illinois-based medical technology and digital health company — publicly traded on the NASDAQ (NASDAQ: GEHC) as an S&P 500 Health Care component — designin
Incyte
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation,
Biogen
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and com
Danaher Corporation
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, man
Revvity
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provid
Compare Becton Dickinson with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Becton Dickinson? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Becton Dickinson Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Becton Dickinson vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →